Shu Kurosaki

Shu Kurosaki, CPA has a long and varied work experience. Shu began their career in 2002 as the Director of Finance at Oculex Pharmaceuticals, Inc., where they worked until the company was sold to Allergan in 2003. In 2004, they moved to MacuSight, Inc., where they held the roles of Corporate Treasurer and Vice President, Finance & Administration and Treasurer / Director of Finance. In 2010, they became Vice President, Finance & Administration / Director of Finance at Digital Air Strike, a digital marketing and social media company specialized in the automotive industry. In 2012, they joined Reset Therapeutics as Chief Financial Officer / VP Finance & Controller. From 2018 to 2019, they were Chief Financial Officer of Synchronicity Pharma, a clinical stage development company focused on treating diseases by restoring the body's circadian rhythm. In 2018, they were also President of Kurobei, Inc. From 2019 to 2020, they held the role of Consulting Head of Finance & Accounting at Enliven Therapeutics. Shu is currently Consulting Head of Finance & Accounting at Perfuse Therapeutics, and will start in the same role at Leal Therapeutics in 2021. In 2018, they also held the role of Finance Accounting Consultant at Novome Biotechnologies.

Shu Kurosaki, CPA attended the University of California, Berkeley, Haas School of Business from 1992 to 1994, where they earned a BS in Business, with emphasis on accounting and marketing. Shu also attended the University of California, Berkeley from 1990 to 1994. In addition, they are a certified public accountant.